Organs-On-Chips 시장 규모는 2024년 921억 6,000만 달러로 평가되었고, 2024년부터 2031년까지 연평균 10.56% 성장하여 2031년에는 1,915억 달러에 달할 것으로 예상됩니다. 장기의 구조와 기능을 미니어처 스케일로 재현한 마이크로플루이딕스 장치입니다. 이 칩에는 장기의 생리적 환경을 모방하도록 배치된 살아있는 인간 세포가 포함되어 있어 연구자들은 통제된 환경에서 장기의 기능, 질병 메커니즘 및 약물 반응을 연구할 수 있습니다. 장기칩(Organ-On-Chips)은 기존의 세포 배양이나 동물 실험보다 더 정확한 모델을 제공함으로써 인간 생물학에 대한 귀중한 통찰력을 제공합니다.
장기칩(Organ-On-Chips)의 용도는 매우 다양하며 다양한 분야에 영향을 미치고 있습니다. 주로 의약품 개발 및 독성 시험에 사용되며, 제약회사는 동물 모델에만 의존하지 않고 새로운 화합물이 인체 조직에 미치는 영향을 평가할 수 있습니다.
또한, 이러한 장치는 질병 과정을 연구하는 데에도 사용할 수 있으며, 연구자들은 보다 생리학적으로 관련된 상황에서 암, 심혈관 질환, 신경 퇴행성 질환과 같은 상태를 조사할 수 있습니다.
세계 장기칩(Organ-On-Chips) 시장을 형성하고 있는 주요 시장 역학
주요 촉진요인
미세 가공의 발전:
미세 가공 기술 혁신은 장기칩(Organ-On-Chips)의 설계와 기능을 향상시키고 정확성과 응용성을 향상시킬 것이며, 2024년 2월에 발표된 미국 국립표준기술연구소(NIST)의 보고서에 따르면 2020년부터 2023년까지 생물의학 응용 분야의 미세 가공 연구에 대한 투자액이 2023년 사이에 35% 증가했습니다.
맞춤형 의료에 대한 수요 증가:
맞춤형 의료로의 전환은 약물 검사 및 질병 모델링을 위한 장기칩(Organ-On-Chips)에 대한 관심을 높이고 맞춤형 치료 솔루션을 제공합니다. 미국 식품의약국(FDA)은 2024년 1월, 2023년 맞춤형 의료 승인 건수가 전년 대비 28% 증가했다고 보고했습니다.
규제적 지원:
의약품 개발 및 독성 시험을 위한 규제 기관의 장기칩(Organ-On-Chips)에 대한 인식이 높아지면서 제약 및 생명공학 산업에서의 채택이 가속화되고 있습니다. 예를 들어, 유럽의약품청(EMA)은 2024년 1월에 전임상시험에서 장기칩(Organ-On-Chips)의 사용에 대한 새로운 가이드라인을 발표하여 규제 과정에서 이 기술이 점점 더 많이 수용되고 있음을 보여주었습니다.
주요 과제
높은 개발 비용:
장기칩(Organ-On-Chips)에 필요한 복잡한 제조 공정과 기술은 막대한 연구개발비로 이어질 수 있습니다.
기술적 한계 :
현재 모델은 인간 장기의 복잡성을 완전히 재현할 수 없어 특정 연구 분야에서의 신뢰성과 적용성을 제한할 수 있습니다.
규제상의 과제:
약물 검사에서 장기칩(Organ-On-Chip)의 수용과 표준화를 위해 진화하는 규제 환경을 탐색하는 것은 보급을 위한 장애물이 될 수 있습니다.
주요 동향
AI 및 머신러닝과의 통합:
AI 기술의 도입으로 데이터 분석 및 예측 모델링이 강화되어 의약품 검사 및 질병 연구에서 장기칩(Organ-On-Chips) 시스템의 정확도가 향상될 것으로 예상됩니다. Organs-On-Chips) 시스템과 결합된 AI의 사용은 2021-2023년 사이에 58% 증가했다고 밝혔습니다.
다장기 모델 확대:
다기관 칩에 대한 관심이 높아짐에 따라 더 복잡한 상호 작용이 가능하고 인간의 생리학을 더 잘 시뮬레이션할 수 있어 약물의 효능과 안전성을 더 잘 평가할 수 있게 됩니다. 예를 들어, 2024년 1월 TissUse GmbH는 'Human-on-a-Chip' 플랫폼을 발표하여 하나의 마이크로플루이딕스 장치로 최대 10가지의 장기 모델을 연결할 수 있게 되었습니다.
질병모델에 대한 집중도:
질병 특이적 모델에 대한 수요 증가는 장기칩(Organ-On-Chips)의 기술 혁신을 촉진하고 암, 심혈관 질환, 신경 퇴행성 질환 등의 질병에 대한 연구를 촉진할 것입니다. 예를 들어, 2024년 2월 에뮬레이트(Emulate, Inc.)는 알츠하이머병 협회와 공동으로 신경 퇴행성 질환의 모델로 특별히 설계된 '브레인 칩'을 개발했다고 발표했습니다.
Organs-On-Chips Market size was valued at USD 92.16 Billion in 2024 and is projected to reach USD 191.5 Billion by 2031, growing at a CAGR of 10.56% from 2024 to 2031. Organs-on-chips are microfluidic devices that replicate the structure and function of human organs at a miniature scale. These chips contain living human cells arranged in a way that mimics the physiological environment of the organs they represent, enabling researchers to study organ functions, disease mechanisms, and drug responses in a controlled setting. By providing a more accurate model than traditional cell culture or animal testing, organs-on-chips offer valuable insights into human biology.
The applications of organs-on-chips are diverse and impactful across various fields. They are primarily used in drug development and toxicity testing, allowing pharmaceutical companies to assess the effects of new compounds on human tissues without relying solely on animal models.
Additionally, these devices can be used to study disease processes, enabling researchers to investigate conditions like cancer, cardiovascular diseases, and neurodegenerative disorders in a more physiologically relevant context.
The key market dynamics that are shaping the global organs-on-chips market include:
Key Drivers
Advancements in Microfabrication:
Innovations in microfabrication technologies enhance the design and functionality of organs-on-chips, improving their accuracy and applicability. According to a report by the National Institute of Standards and Technology (NIST) published in February 2024, investments in microfabrication research for biomedical applications increased by 35% between 2020 and 2023.
Rising Demand for Personalized Medicine:
The shift towards personalized medicine fuels interest in organs-on-chips for drug testing and disease modeling, providing tailored therapeutic solutions. The U.S. Food and Drug Administration (FDA) reported in January 2024 that the number of personalized medicine approvals increased by 28% in 2023 compared to the previous year.
Regulatory Support:
Increasing recognition of organs-on-chips by regulatory bodies for drug development and toxicity testing accelerates adoption in pharmaceutical and biotech industries. For instance, in January 2024, the European Medicines Agency (EMA) released new guidelines for the use of organs-on-chips in preclinical drug testing, signaling growing acceptance of this technology in regulatory processes.
Key Challenges:
High Development Costs:
The complex manufacturing processes and technology required for organs-on-chips can lead to significant research and development expenses.
Technical Limitations:
Current models may not fully replicate the complexity of human organs, limiting their reliability and applicability in certain research areas.
Regulatory Challenges:
Navigating the evolving regulatory landscape for acceptance and standardization of organs-on-chips in drug testing poses hurdles for widespread adoption.
Key Trends
Integration with AI and Machine Learning:
The incorporation of AI technologies enhances data analysis and predictive modeling, improving the accuracy of organ-on-chip systems in drug testing and disease research. According to a report by the National Institutes of Health (NIH) published in January 2024, the use of AI in conjunction with organ-on-chip systems increased by 58% between 2021 and 2023.
Expansion of Multi-Organ Models:
Increasing interest in multi-organ chips allows for more complex interactions and better simulation of human physiology, advancing drug efficacy and safety assessments. For instance, in January 2024, TissUse GmbH unveiled their "Human-on-a-Chip" platform, capable of connecting up to ten different organ models in a single microfluidic device.
Focus on Disease Modeling:
Growing demand for disease-specific models drives innovation in organs-on-chips, facilitating research on conditions like cancer, cardiovascular diseases, and neurodegenerative disorders. For instance, in February 2024, Emulate, Inc. announced a collaboration with the Alzheimer's Association to develop a "Brain-Chip" specifically designed to model neurodegenerative disorders.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Here is a more detailed regional analysis of the global organs-on-chips market:
North America
North America is dominating the organs-on-Chips market, driven by substantial investments in research and development, a robust biotechnology sector, and supportive regulatory frameworks. The U.S. National Institutes of Health (NIH) reported allocating USD 89 Million in fiscal year 2023 to support research on microphysiological systems, including organs-on-chips, highlighting the region's commitment to advancing this technology. This significant funding has accelerated the development and adoption of organs-on-chips across pharmaceutical companies, academic institutions, and research organizations in North America.
The region's dominance is further solidified by the presence of leading market players and a growing emphasis on reducing animal testing in drug development. According to the U.S. Food and Drug Administration (FDA), the average cost to develop a new drug exceeds USD 2.6 Billion, with a significant portion attributed to preclinical testing. Organs-on-chips technology offers a promising solution to reduce these costs and improve the efficiency of drug discovery processes, driving its adoption across the pharmaceutical industry in North America.
Recent developments in the market have seen key players introducing innovative solutions and expanding their product offerings. In February 2024, Emulate Inc. announced the launch of a new multi-organ chip platform capable of simulating complex organ interactions, aimed at enhancing drug toxicity studies. Additionally, CN Bio Innovations reported in December 2023 a collaborative agreement with a major U.S. pharmaceutical company to develop custom organ-on-chip models for respiratory disease research, demonstrating the growing industry adoption of this technology in North America.
Asia Pacific
The Asia Pacific region is experiencing rapid growth in the organs-on-chips market, driven by increasing investment in life sciences research, rising demand for personalized medicine, and government initiatives to promote innovative healthcare technologies.
According to the Japan Agency for Medical Research and Development (AMED), the country invested approximately 146 billion yen (USD 1.3 Billion) in fiscal year 2022 for medical research and development, with a significant portion allocated to advanced biotechnologies like organs-on-chips. This substantial funding has catalyzed research activities and collaborations between academic institutions and industry players, fostering the adoption of organs-on-chips technology across the region.
The market's growth is further propelled by the region's large and diverse patient population, which presents unique opportunities for drug discovery and personalized medicine applications. China's National Medical Products Administration (NMPA) reported in 2023 that the country had over 5,000 new drug applications under review, highlighting the immense potential for organs-on-chips technology to streamline the drug development process. This has led to increased collaboration between local pharmaceutical companies and organs-on-chips developers to create more efficient and cost-effective drug screening methods.
The Global Organs-On-Chips Market is segmented on the basis of End-User, Application, Type, And Geography.
Based on the End-User, the Global Organs-On-Chips Market is segmented into Pharmaceutical and biotechnology companies, Academic, Research institutes. In the organs-on-chips market, pharmaceutical and biotechnology companies are the dominant end users, leveraging these technologies to enhance drug development processes and improve safety assessments. Meanwhile, the academic segment is experiencing rapid growth, fueled by increasing research initiatives and funding aimed at understanding complex biological systems. This trend underscores the importance of innovative educational tools in advancing scientific research and fostering collaboration between academia and industry.
Based on the Application, the Global Organs-On-Chips Market is segmented into Drug Discovery, Toxicology Research, Physiological Model, and Others. In the organs-on-chips market, the drug discovery segment is currently the dominant application, as it plays a crucial role in streamlining the drug development process and improving success rates. However, the toxicology research segment is experiencing rapid growth, driven by the increasing need for safer and more effective testing methods that reduce reliance on animal models. This shift reflects a broader trend toward regulatory compliance and ethical considerations in biomedical research.
Based on Type, the Global Organs-On-Chips Market is segmented into Heart on chip, Human on chip, Intestine on chip, Kidney on chip, Liver on chip, and Lung on chip. In the organs-on-chips market, the liver on chip segment is currently dominating, driven by its critical role in drug metabolism and toxicity testing. However, the heart on chip segment is rapidly growing, fueled by increasing interest in cardiovascular disease research and personalized medicine applications. This trend highlights the rising demand for innovative models that can replicate complex organ functions for more accurate drug testing and development.
Based on Geography, the Global Organs-On-Chips Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the organs-on-chips market, North America currently dominates due to its robust biotechnology sector and significant investments in research and development. However, the Asia Pacific region is emerging rapidly, driven by increasing government support for advanced biomedical technologies and a growing emphasis on personalized medicine. This shift indicates a strong potential for growth in Asia Pacific as it invests in innovative healthcare solutions.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.